G Dailey

Summary

Affiliation: Scripps Clinic
Country: USA

Publications

  1. ncbi Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus
    G Dailey
    Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 23:1311-20. 2001
  2. ncbi Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Curr Med Res Opin 20:2007-14. 2004
  3. ncbi Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA
    Am J Manag Care 14:25-30. 2008
  4. ncbi New strategies for basal insulin treatment in type 2 diabetes mellitus
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 26:889-901. 2004
  5. ncbi Improving oral pharmacologic treatment and management of type 2 diabetes
    George E Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, 10666 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Manag Care 13:41-7. 2004
  6. ncbi Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Med 116:223-9. 2004
  7. ncbi Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA
    Expert Opin Pharmacother 4:1417-30. 2003
  8. ncbi Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 24:1426-38. 2002
  9. ncbi Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients
    G Dailey
    Scripps Clinic, La Jolla, CA, USA
    J Int Med Res 30:71-9. 2002
  10. ncbi Insulin secretagogues: who, what, when, and how?
    George Dailey
    Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Diab Rep 5:329-32. 2005

Detail Information

Publications16

  1. ncbi Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus
    G Dailey
    Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 23:1311-20. 2001
    ..Drug use patterns among patients with type 2 diabetes mellitus have been studied in the general population but not specifically in the Medicaid population...
  2. ncbi Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Curr Med Res Opin 20:2007-14. 2004
    ..To review results from clinical studies utilizing basal insulin therapy and discuss the impact of intensive glycemic control using forced-titration algorithms to fine-tune insulin dosing in patients with type 2 diabetes mellitus...
  3. ncbi Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA
    Am J Manag Care 14:25-30. 2008
    ....
  4. ncbi New strategies for basal insulin treatment in type 2 diabetes mellitus
    George Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 26:889-901. 2004
    ..Reassessment of current insulin treatment strategies leading to restoration of glycemic control is essential to prevent or stop the progression of type 2 DM and its complications...
  5. ncbi Improving oral pharmacologic treatment and management of type 2 diabetes
    George E Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, 10666 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Manag Care 13:41-7. 2004
    ..These measures, along with new oral treatment options, may allow patients and their health care providers to achieve better glycemic control, improve adherence, and reduce the costs associated with this progressive and chronic disease...
  6. ncbi Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Med 116:223-9. 2004
    ..0% and < or =10.0%)...
  7. ncbi Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA
    Expert Opin Pharmacother 4:1417-30. 2003
    ..Glyburide/metformin tablets are an effective option for optimising the control of blood glucose in Type 2 diabetic patients and appear to enhance adherence to therapy...
  8. ncbi Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study
    George E Dailey
    Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 24:1426-38. 2002
    ....
  9. ncbi Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients
    G Dailey
    Scripps Clinic, La Jolla, CA, USA
    J Int Med Res 30:71-9. 2002
    ..Compliance with sulfonylurea or metformin monotherapy was 45% greater than with polytherapy...
  10. ncbi Insulin secretagogues: who, what, when, and how?
    George Dailey
    Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Diab Rep 5:329-32. 2005
    ..The large majority of the effect can be seen within a week, making them very attractive when rapid lowering of glucose is needed. An understanding of the principles will facilitate more effective use of initial and combination therapy...
  11. ncbi Optimum management of type 2 diabetes--timely introduction, optimization and intensification of basal insulin
    G Dailey
    Department of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, San Diego, CA 92037, USA
    Diabetes Obes Metab 10:5-13. 2008
    ....
  12. ncbi Beyond insulin replacement: addressing the additional needs of the diabetes patient
    G Dailey
    Department of Diabetes and Endocrinology, Scripps Clinic Torrey Pines, San Diego, CA 92037, USA
    Diabetes Obes Metab 10:83-97. 2008
    ..In this review, the clinical properties of these agents and potential treatment pathways to best use these agents are discussed for improving the management of T2DM and cardiovascular risk...
  13. ncbi Using prandial insulin to achieve glycemic control in type 2 diabetes
    George E Dailey
    Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA 92037, USA
    J Fam Pract 56:735-42. 2007
  14. ncbi Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
    Lawrence Blonde
    Department of Internal Medicine, Oschner Clinic Foundation, New Orleans, LA, USA
    Curr Med Res Opin 20:565-72. 2004
    ..This retrospective chart review examined the overall gastrointestinal (GI) tolerability of both formulations...
  15. ncbi Early insulin: an important therapeutic strategy
    George E Dailey
    Diabetes Care 28:220-1. 2005
  16. ncbi The metabolic syndrome: a call to action
    Antonio M Gotto
    Office of the Dean, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Coron Artery Dis 17:77-80. 2006
    ..While more research is needed to understand the pathology of the metabolic syndrome, there is no ambiguity that physicians should treat cardiovascular risk factors in individuals with metabolic syndrome...